257 related articles for article (PubMed ID: 35628501)
21. Markers of airway inflammation in pulmonary diseases assessed by induced sputum.
Dragonieri S; Tongoussouva O; Zanini A; Imperatori A; Spanevello A
Monaldi Arch Chest Dis; 2009 Sep; 71(3):119-26. PubMed ID: 19999958
[TBL] [Abstract][Full Text] [Related]
22. Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma.
Fujii K; Nakamura H; Nishimura T
Expert Rev Proteomics; 2017 Apr; 14(4):373-386. PubMed ID: 28271730
[TBL] [Abstract][Full Text] [Related]
23. Proteomics-based diagnosis of chronic obstructive pulmonary disease: the hunt for new markers.
Casado B; Iadarola P; Luisetti M; Kussmann M
Expert Rev Proteomics; 2008 Oct; 5(5):693-704. PubMed ID: 18937559
[TBL] [Abstract][Full Text] [Related]
24. Induced sputum proteome in healthy subjects and asthmatic patients.
Gharib SA; Nguyen EV; Lai Y; Plampin JD; Goodlett DR; Hallstrand TS
J Allergy Clin Immunol; 2011 Dec; 128(6):1176-1184.e6. PubMed ID: 21906793
[TBL] [Abstract][Full Text] [Related]
25. Proteomics-based biomarkers in chronic obstructive pulmonary disease.
Chen H; Wang D; Bai C; Wang X
J Proteome Res; 2010 Jun; 9(6):2798-808. PubMed ID: 20387909
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary biomarkers based on alterations in protein expression after exposure to arsenic.
Lantz RC; Lynch BJ; Boitano S; Poplin GS; Littau S; Tsaprailis G; Burgess JL
Environ Health Perspect; 2007 Apr; 115(4):586-91. PubMed ID: 17450228
[TBL] [Abstract][Full Text] [Related]
27. Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with
Pattison SH; Gibson DS; Johnston E; Peacock S; Rivera K; Tunney MM; Pappin DJ; Elborn JS
Eur Respir J; 2017 Jul; 50(1):. PubMed ID: 28679606
[TBL] [Abstract][Full Text] [Related]
28. Recent insights into human bronchial proteomics - how are we progressing and what is next?
Tan HW; Xu YM; Wu DD; Lau ATY
Expert Rev Proteomics; 2018 Feb; 15(2):113-130. PubMed ID: 29260600
[TBL] [Abstract][Full Text] [Related]
29. Respiratory proteomics: from descriptive studies to personalized medicine.
Teran LM; Montes-Vizuet R; Li X; Franz T
J Proteome Res; 2015 Jan; 14(1):38-50. PubMed ID: 25382407
[TBL] [Abstract][Full Text] [Related]
30. Elevated sputum BPIFB1 levels in smokers with chronic obstructive pulmonary disease: a longitudinal study.
Gao J; Ohlmeier S; Nieminen P; Toljamo T; Tiitinen S; Kanerva T; Bingle L; Araujo B; Rönty M; Höyhtyä M; Bingle CD; Mazur W; Pulkkinen V
Am J Physiol Lung Cell Mol Physiol; 2015 Jul; 309(1):L17-26. PubMed ID: 25979078
[TBL] [Abstract][Full Text] [Related]
31. Asthma and COPD proteomics: current approaches and future directions.
Terracciano R; Pelaia G; Preianò M; Savino R
Proteomics Clin Appl; 2015 Feb; 9(1-2):203-20. PubMed ID: 25504544
[TBL] [Abstract][Full Text] [Related]
32. Biomarker discovery in asthma and COPD by proteomic approaches.
Rossi R; De Palma A; Benazzi L; Riccio AM; Canonica GW; Mauri P
Proteomics Clin Appl; 2014 Dec; 8(11-12):901-15. PubMed ID: 25186471
[TBL] [Abstract][Full Text] [Related]
33. Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum.
Röpcke S; Holz O; Lauer G; Müller M; Rittinghausen S; Ernst P; Lahu G; Elmlinger M; Krug N; Hohlfeld JM
PLoS One; 2012; 7(10):e46207. PubMed ID: 23056262
[TBL] [Abstract][Full Text] [Related]
34. Proteomic analysis of serum and sputum analytes distinguishes controlled and poorly controlled asthmatics.
Kasaian MT; Lee J; Brennan A; Danto SI; Black KE; Fitz L; Dixon AE
Clin Exp Allergy; 2018 Jul; 48(7):814-824. PubMed ID: 29665127
[TBL] [Abstract][Full Text] [Related]
35. Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics.
López-Sánchez LM; Jurado-Gámez B; Feu-Collado N; Valverde A; Cañas A; Fernández-Rueda JL; Aranda E; Rodríguez-Ariza A
Am J Physiol Lung Cell Mol Physiol; 2017 Oct; 313(4):L664-L676. PubMed ID: 28619761
[TBL] [Abstract][Full Text] [Related]
36. Sputum trace metals are biomarkers of inflammatory and suppurative lung disease.
Gray RD; Duncan A; Noble D; Imrie M; O'Reilly DS; Innes JA; Porteous DJ; Greening AP; Boyd AC
Chest; 2010 Mar; 137(3):635-41. PubMed ID: 19801580
[TBL] [Abstract][Full Text] [Related]
37. Lung tissue proteomics identifies elevated transglutaminase 2 levels in stable chronic obstructive pulmonary disease.
Ohlmeier S; Nieminen P; Gao J; Kanerva T; Rönty M; Toljamo T; Bergmann U; Mazur W; Pulkkinen V
Am J Physiol Lung Cell Mol Physiol; 2016 Jun; 310(11):L1155-65. PubMed ID: 27084846
[TBL] [Abstract][Full Text] [Related]
38. Characterization of sputum biomarkers for asthma-COPD overlap syndrome.
Gao J; Iwamoto H; Koskela J; Alenius H; Hattori N; Kohno N; Laitinen T; Mazur W; Pulkkinen V
Int J Chron Obstruct Pulmon Dis; 2016; 11():2457-2465. PubMed ID: 27757028
[TBL] [Abstract][Full Text] [Related]
39. Proteomics as the tool to search for lung disease markers in bronchoalveolar lavage.
Noël-Georis I; Bernard A; Falmagne P; Wattiez R
Dis Markers; 2001; 17(4):271-84. PubMed ID: 11790894
[TBL] [Abstract][Full Text] [Related]
40. Bronchoalveolar Lavage: Quantitative Mass Spectrometry-Based Proteomics Analysis in Lung Diseases.
Carvalho AS; Matthiesen R
Methods Mol Biol; 2017; 1619():487-494. PubMed ID: 28674906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
